ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene
ALK internal deletions of nonkinase domain exons occur in 0.01% of lung cancers with ALK genomic aberrations. We report a lung adenocarcinoma with a previously undescribed somatic ALK deletion of exons 2 to 19 with dramatic and sustained (>23 mo) response to alectinib. Our and other reported case...
Saved in:
Published in | JTO clinical and research reports Vol. 4; no. 4; p. 100489 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.04.2023
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | ALK internal deletions of nonkinase domain exons occur in 0.01% of lung cancers with ALK genomic aberrations. We report a lung adenocarcinoma with a previously undescribed somatic ALK deletion of exons 2 to 19 with dramatic and sustained (>23 mo) response to alectinib. Our and other reported cases with ALK nonkinase domain deletions (between introns and exons 1–19) can display positive results in nonsequencing-based lung cancer diagnostic tests (such as immunohistochemistry) used to screen for more common ALK rearrangements. This case report emphasizes that “ALK-driven” lung cancers should be expanded to encompass those harboring not only ALK rearrangements with other genes but also ALK nonkinase domain deletions. |
---|---|
ISSN: | 2666-3643 2666-3643 |
DOI: | 10.1016/j.jtocrr.2023.100489 |